Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Everett Stone
University of Texas, Austin, Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
GMA, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The covered individual holds equity interest in GMA, LLC. The Covered Individual conducts sponsored research on intellectual property that has been assigned to GMA, LLC. Aeglea, LLC develops protein drugs related to the technology owned by GMA, LLC. The business interests of GMA, LLC and Aeglea, LLC overlap with the covered individuals area of research.
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.
Major drawbacks to current treatments of Prostate cancer (PCa) are resistance to androgen ablation therapy and chemotherapy associated toxicities that severely compromise quality of life. The finding that PCa (and other cancer types) display an excessive requirement of the amino acid L-cysteine relative to non-malignant tissues has led to the development of a completely novel therapeutic approach to treat PCa that exploits this critical vulnerability by using an engineered human enzyme to deprive tumor cells of L-cysteine. Most if not all normal tissue can make L-cysteine from the essential amino acid L-Methionine, thus only tumors are highly impacted when L-cysteine is unavailable.
Filed on August 01, 2014.
Tell us what you know about Everett Stone's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Everett Stone filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Everett Stone | University of Texas, Austin | Conflict of Interest | Aeglea Biotherapeutics | $20,000 - $39,999 |
| Everett Stone | University of Texas, Austin | Conflict of Interest | Aeglea, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.